Boston Scientific, US10117L1017

Boston Scientific stock falls after a cyberattack and $46.71 quote

Published on 08/28/2026 at 20:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Boston Scientific stock trades at $46.71 as a cyberattack disrupts global operations and the latest quarter showed $5.44 billion in revenue and $0.86 in EPS.

Draufsicht-Flatlay mit Aktienzertifikat, ISIN-Karte US10117L1017, Koronarstent und Endoskop auf Marmor
Boston Scientific Corp. Aktienzertifikat-Flatlay mit ISIN-Karte US10117L1017 und Herzkathetersystemen auf Marmor arrangiert, Illustration mit AI erstellt.

Boston Scientific stock (ISIN US10117L1017) trades at $46.71 as of August 28, 2026, while a cyberattack has disrupted parts of its global operations and the latest reported quarter delivered $5.44 billion in revenue and $0.86 in adjusted EPS.

Cyber disruption lands first

Boston Scientific said the incident is affecting systems used to process customer orders and ship products worldwide, and a report summarized the stock as down 3.2% with shares opening at $46.64 and a market value of $67.59 billion.

The same report put the 52-week range at $42.20 to $109.50, the 50-day moving average at $46.53, and the 200-day moving average at $56.72, leaving the stock close to the short-term trend line but well below the longer one.

Latest quarter still matters

The most recent reported quarter, on July 29, 2026, showed revenue of $5.44 billion, up 7.5% year over year, with adjusted EPS of $0.86 versus $0.75 a year earlier.

That quarter also carried a net margin of 17.50% and operating margin of 22.90%, while full-year 2026 guidance stood at $3.28 to $3.32 in EPS, a range that frames how much the cyber issue can matter if shipments stay under pressure.

Among peers, the setup looks mixed: Boston Scientific's consensus target in a market-data snapshot was $71.62, yet the shares were quoted at $46.69 intraday, a gap that leaves room for debate on valuation versus execution risk.

Product angle

Boston Scientific's portfolio spans devices for less-invasive procedures in cardiovascular, digestive, urologic, pulmonary and chronic-pain care, which means order delays can flow quickly into procedure timing and revenue recognition.

Stock level

Boston Scientific stock last changed hands at $46.71 as of August 28, 2026, with a market capitalization of $69.81 billion in the same data set. The quote sits just above the 50-day moving average of $46.54 and below the 200-day average of $68.42.

Fact box

Company: Boston Scientific Corporation
ISIN: US10117L1017
Ticker: BSX
Exchange: NYSE
Sector / Industry: Health Care / Medical Devices
Index membership: S&P 500

Disclaimer...

en | US10117L1017 | BOSTON SCIENTIFIC | boerse | 70016820 | bgmi